SEC Filings | Onyx Pharmaceuticals

You are provided a hyperlink to the 10KWizard.com web site. ONYX PHARMACEUTICALS INC does not maintain or provide information directly to this site.

ONYX PHARMACEUTICALS INC makes no representations or warranties with respect to the information contained herein and takes no responsibility for supplementing, updating, or correcting any such information.

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

Symbol
ONXX
Last
43.71 +0.22
Open
43.46
High
43.81
Low
42.49
Volume
1139204

Latest News

05/19/2011

Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
05/18/2011

Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
05/18/2011

Nexavar Data To Be Presented at American Society of Clinical Oncology Annual Meeting
05/18/2011

Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting

05/19/2011

Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
05/18/2011

Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
05/18/2011

Nexavar Data To Be Presented at American Society of Clinical Oncology Annual Meeting
05/18/2011

Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting
05/6/2021

Onyx Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference
05/4/2021

Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
04/28/2011

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
04/21/2011

Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
03/28/2011

Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
03/11/2021

Onyx Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
03/2/2022

Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
02/24/2011

Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination with Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
02/23/2011

Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
02/15/2011

Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results Teleconference and Webcast
02/3/2021

Onyx Pharmaceuticals Appoints Bill Ringo to Board of Directors
01/31/2011

Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
01/4/2021

Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference

12/7/2021

Onyx Pharmaceuticals Announces Positive Complete Results from Carfilzomib Phase 2b Study
12/6/2021

Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
11/18/2010

Onyx Pharmaceuticals Announces December 2010 Investor Events
11/10/2021

Onyx Pharmaceuticals to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11/9/2021

Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting
11/4/2021

Onyx Pharmaceuticals to Present at the Credit Suisse 2010 Healthcare Conference
11/3/2021

Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue
10/26/2010

Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
10/7/2021

Onyx Pharmaceuticals Provides Status Update on Carfilzomib
10/7/2021

Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib
10/7/2021

Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
09/16/2010

Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
09/8/2021

Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan
09/7/2021

Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
08/4/2021

Onyx Pharmaceuticals Reports Second Quarter 2010 Financial Results; Nexavar Global Net Sales Increase 17% vs. Prior Year
08/3/2021

Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference
07/28/2010

Onyx Pharmaceuticals Announces Second Quarter 2010 Financial Results Teleconference and Webcast
07/26/2010

Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data from Phase 2b Study
07/23/2010

Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
07/21/2010

Onyx Pharmaceuticals Initiates a Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma
06/14/2010

Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide Update on Nexavar
06/14/2010

Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
06/8/2021

Onyx Pharmaceuticals to Present at the Goldman Sachs 31st Annual Global Healthcare Conference
06/8/2021

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at the 15th Congress of the European Hematology Association
06/5/2021

Onyx Pharmaceuticals’ Carfilzomib Continues to Demonstrate Encouraging Results in Ongoing Phase 2 Multiple Myeloma Study
06/4/2021

Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
06/1/2022

Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
05/21/2010

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
05/20/2010

Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
05/11/2021

Onyx Pharmaceuticals to Present at the Baird 2010 Growth Stock Conference
05/5/2021

Onyx Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference
05/4/2021

S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
05/4/2021

Onyx Pharmaceuticals Reports First Quarter 2010 Financial Results; Nexavar Global Net Sales Increase 20% Over First Quarter 2009
04/27/2010

Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast
03/16/2010

Onyx Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
03/1/2022

Onyx Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
02/23/2010

Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
02/16/2010

Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2009 Financial Results Teleconference and Webcast
02/2/2022

Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
02/2/2022

Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma
02/1/2022

Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
01/5/2021

Onyx Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

12/11/2021

Nexavar in Combination with Chemotherapy Demonstrates Activity in Patients with Advanced Breast Cancer in Two Phase 2 Studies
12/10/2021

Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
12/7/2021

Carfilzomib Data Demonstrate Promising Efficacy and Tolerability Signals in Ongoing Phase 1b/2 Combination Study with Lenalidomide and Low Dose Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
12/7/2021

Carfilzomib Demonstrates Encouraging Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma in an Ongoing Phase 2 Study
12/6/2021

Carfilzomib Safety Data from Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
12/4/2021

Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
11/25/2009

Onyx Pharmaceuticals Announces December 2009 Investor Events
11/16/2009

Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
11/11/2021

Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
11/10/2021

Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and ONX 0803 at 51st American Society of Hematology Annual Meeting
11/4/2021

Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
11/3/2021

Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
10/29/2009

Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
10/27/2009

Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
10/23/2009

Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
10/12/2021

Onyx Pharmaceuticals Announces Webcast to Discuss Multiple Myeloma Market and Carfilzomib Clinical Overview
10/12/2021

Onyx Pharmaceuticals to Acquire Proteolix, Inc.
10/11/2021

Onyx Pharmaceuticals Announces Investor Teleconference and Webcast
09/30/2009

Results Reported for Exploratory Phase 2 Study of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
09/28/2009

Onyx Pharmaceuticals Initiates Phase 1 Study of ONX 0801 in Advanced Solid Tumors
09/24/2009

Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
09/23/2009

Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
09/15/2009

Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
09/4/2021

Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
09/2/2022

Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
08/6/2021

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
08/6/2021

Onyx Pharmaceuticals to Present at the 29th Annual Canaccord Adams Global Growth Conference
08/4/2021

Onyx Pharmaceuticals Announces Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
08/4/2021

Onyx Pharmaceuticals Reports Second Quarter 2009 Financial Results; Nexavar Global Net Sales Reach $201 Million, 19% Increase Over Second Quarter 2008
07/29/2009

Onyx Pharmaceuticals Announces Second Quarter 2009 Financial Results Teleconference And Webcast
07/22/2009

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
06/2/2022

Onyx Pharmaceuticals To Present At The Goldman Sachs 30th Annual Global Healthcare Conference
06/1/2022

Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
05/28/2009

Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer
05/20/2009

Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
05/17/2009

Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
05/14/2009

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
05/12/2021

Onyx Pharmaceuticals To Present At The Deutsche Bank 34th Annual Health Care Conference
05/6/2021

Onyx Pharmaceuticals Reports First Quarter 2009 Financial Results
05/5/2021

Onyx Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
04/28/2009

Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
04/26/2009

Onyx Pharmaceuticals Announces A Teleconference And Webcast To Provide An Update On Nexavar
04/26/2009

Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
03/10/2021

Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
03/3/2021

Onyx Pharmaceuticals To Present At The Barclays Capital Global Healthcare Conference
02/23/2009

Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
02/12/2021

Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
01/6/2021

Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors from S*BIO
01/5/2021

Onyx Pharmaceuticals To Present At The 27th Annual JPMorgan Healthcare Conference

12/23/2008

Onyx Pharmaceuticals Names Matthew K. Fust Executive Vice President And Chief Financial Officer
11/6/2021

Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent from BTG International
11/6/2021

Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results
11/5/2021

Onyx Pharmaceuticals To Present At The 2008 Credit Suisse Health Care Conference
10/31/2008

New Analyses Confirm Nexavar’s Efficacy and Safety In Multiple Patient Subsets with Liver Cancer
10/29/2008

Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference And Webcast
09/18/2008

Onyx Pharmaceuticals To Present At UBS Global Life Sciences Conference
08/21/2008

Bayer And Onyx Begin Enrollment In Storm Trial Studying Nexavar As Adjuvant Therapy For Patients With Liver Cancer
08/15/2008

Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
08/5/2021

Onyx Pharmaceuticals Reports Second Quarter And Six-Month 2008 Financial Results
07/31/2008

Onyx Pharmaceuticals To Present At Bank Of America 2008 Specialty Pharmaceuticals Conference
07/30/2008

Onyx Pharmaceuticals Announces Second Quarter 2008 Financial Results Teleconference And Webcast
07/28/2008

Nexavar Approved for Liver Cancer in China
07/23/2008

The New England Journal of Medicine Publishes Nexavar Study Demonstrating Significant Improvement in Overall Survival in Patients with Liver Cancer
06/19/2008

Onyx Pharmaceuticals To Present At Jefferies 2nd Annual Healthcare Conference
06/4/2021

Onyx Pharmaceuticals To Present At Goldman Sachs 29th Annual Global Healthcare Conference
06/2/2022

New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
05/16/2008

Nexavar Significantly Improves Overall Survival By 47 Percent In Asia-Pacific Liver Cancer Study
05/16/2008

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
05/8/2021

Onyx Pharmaceuticals To Present At Bank Of America Health Care Conference
05/6/2021

Onyx Pharmaceuticals Reports 2008 First Quarter Results
05/5/2021

Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game
04/29/2008

Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference And Webcast
04/24/2008

Onyx Pharmaceuticals To Present At Morgan Stanley Global Healthcare Unplugged Conference
03/11/2021

Onyx Pharmaceuticals To Present At Lehman Brothers Global Healthcare Conference
03/11/2021

Onyx Pharmaceuticals To Present At Cowen And Company Health Care Conference
02/26/2008

Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
02/19/2008

Onyx Pharmaceuticals Reports Fourth Quarter And Twelve-Month 2007 Financial Results
02/19/2008

Onyx Pharmaceuticals Announces a Teleconference and Webcast To Provide An Update On Nexavar And Report Full Year 2007 Financial Results
02/18/2008

Onyx Pharmaceuticals Announces A Teleconference And Webcast To Provide An Update On Nexavar; Previously Announced Fourth Quarter And Full Year 2007 Financial Results Teleconference Rescheduled
02/18/2008

Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
02/6/2021

Onyx Pharmaceuticals To Present At BIO CEO & Investor Conference
01/25/2008

Onyx Pharmaceuticals To Present At Wachovia Healthcare Conference
01/2/2022

Onyx Pharmaceuticals To Present At JPMorgan Healthcare Conference

11/19/2007

Nexavar First FDA-Approved Drug Therapy for Liver Cancer
11/6/2021

Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2007 Financial Results
10/30/2007

Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
10/25/2007

Onyx Pharmaceuticals Announces Third Quarter 2007 Financial Results Teleconference and Webcast
10/4/2021

Onyx Pharmaceuticals Announces Management Changes
10/3/2021

Onyx Pharmaceuticals To Present At Biotechnology Industry Organization Investor Forum
09/21/2007

Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
09/18/2007

Onyx Pharmaceuticals To Present At UBS Global Life Sciences Conference
08/27/2007

Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
08/20/2007

Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
08/7/2021

Onyx Pharmaceuticals Reports Second Quarter And Six-Month 2007 Financial Results
07/31/2007

Onyx Pharmaceuticals Announces Second Quarter 2007 Financial Results Teleconference and Webcast
06/27/2007

Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
06/21/2007

Onyx Announces Pricing of Public Offering
06/19/2007

Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
06/18/2007

Onyx Announces Proposed Public Offering of Common Stock
06/4/2021

Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
05/25/2007

Onyx Pharmaceuticals Announces An Analyst Briefing
05/23/2007

Onyx Pharmaceuticals To Present At Bank Of America 2007 Health Care Conference
05/9/2021

Onyx Pharmaceuticals Reports First Quarter 2007 Financial Results
05/2/2022

Onyx Pharmaceuticals Announces First Quarter 2007 Financial Results Teleconference And Webcast
04/27/2007

Onyx Pharmaceuticals To Present At Morgan Stanley Global Healthcare Unplugged Conference
03/15/2007

Onyx Pharmaceuticals To Present At Lehman Global Healthcare Conference
03/8/2021

Onyx Pharmaceuticals To Present At Cowen Health Care Conference
02/15/2007

Onyx Pharmaceuticals Reports Fourth Quarter And Year-End 2006 Financial Results
02/12/2021

Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
02/12/2021

Onyx Pharmaceuticals Announces A Teleconference And Webcast To Provide An Update On Nexavar
02/9/2021

Onyx Pharmaceuticals to Present at BIO CEO and Investor Conference
02/8/2021

Onyx Pharmaceuticals Announces Fourth Quarter and Year-End 2006 Financial Results Teleconference and Webcast
02/1/2022

Onyx Pharmaceuticals To Present At Merrill Lynch Conference
01/24/2007

Onyx Pharmaceuticals To Present At Wachovia Small And Mid-Cap Conference
01/10/2021

Bayer and Onyx Announce Pivotal Nexavar® Kidney Cancer Study Published in New England Journal of Medicine
01/2/2022

Onyx Pharmaceuticals To Present At JPMorgan Healthcare Conference

12/4/2021

Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
12/4/2021

Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
11/7/2021

Onyx Pharmaceuticals Reports Third Quarter And Nine-Month 2006 Financial Results
11/1/2022

Onyx Pharmaceuticals Announces Third Quarter 2006 Financial Results Teleconference And Webcast
10/12/2021

Onyx Pharmaceuticals to Present at BIO Investor Forum Conference
09/29/2006

Onyx Secures Equity Financing Commitment
08/8/2021

Onyx Pharmaceuticals Reports Second Quarter And Six-Month 2006 Financial Results
08/1/2022

Onyx Pharmaceuticals Announces Second Quarter 2006 Financial Results Teleconference And Webcast
07/24/2006

Nexavar Approved by European Commission for the Treatment of Advanced Kidney Cancer
07/20/2006

Nexavar Receives FDA Fast Track Designation for Skin Cancer
06/13/2006

Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
06/12/2021

Onyx Names Laura A. Brege Executive Vice President And Chief Business Officer
06/6/2021

Onyx Pharmaceuticals To Present At Two Upcoming Healthcare Conferences
06/5/2021

Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
06/1/2022

Onyx Pharmaceuticals To Webcast Analyst Briefing
05/25/2006

Onyx Pharmaceuticals To Present At Friedman Billings Ramsey Growth Investor Conference
05/10/2021

Onyx Pharmaceuticals To Present At Bank Of America Healthcare Conference
05/4/2021

Onyx Pharmaceuticals Reports First Quarter 2006 Financial Results
05/3/2021

Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
04/28/2006

Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use
04/27/2006

Onyx Pharmaceuticals Announces First Quarter 2006 Financial Results Teleconference And Webcast
04/27/2006

Onyx Pharmaceuticals To Present At Morgan Stanley Global Healthcare Unplugged Conference
04/26/2006

FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
04/18/2006

European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
03/30/2006

Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
03/24/2006

Onyx Pharmaceuticals To Present At Future Leaders In The Biotech Industry Conference
03/2/2022

Onyx Pharmaceuticals To Present At Two Upcoming Healthcare Conferences
02/16/2006

Onyx Pharmaceuticals Reports Fourth Quarter And Year-End 2005 Financial Results
02/16/2006

Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) Tablets in Combination With Two Chemotherapeutic Agents
02/9/2021

Onyx Pharmaceuticals Announces Fourth Quarter And Year-End 2005 Financial Results Teleconference And Webcast
02/8/2021

Onyx Pharmaceuticals To Present At BIO CEO & Investor Conference
01/31/2006

Onyx Pharmaceuticals To Present At Merrill Lynch Global Pharmaceutical, Biotechnology And Medical Device Conference
01/5/2021

Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference

Investors

Latest News